Charlene Hu, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
11 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hu’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A79330 · Current
Licensed to practise in California · since 2002 · expires 2028-05-31 · Chekiang Medical University Aka Zhejiang Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$232,783
Medicare paid this office $232,783 for 677 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 391 | $75,180 | $111 |
| Botox | 21 | $42,713 | None |
| Long return visit (40+ min) | 150 | $31,650 | $154 |
| New patient visit (45+ min) | 179 | $26,112 | $146 |
| Short return visit (20+ min) | 220 | $22,876 | $77 |
See all 13 services
| Return visit (30+ min) | 391 | $75,180 | $111 |
| Botox | 21 | $42,713 | None |
| Long return visit (40+ min) | 150 | $31,650 | $154 |
| New patient visit (45+ min) | 179 | $26,112 | $146 |
| Short return visit (20+ min) | 220 | $22,876 | $77 |
| New patient visit (60+ min) | 42 | $8,210 | $195 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 21 | $7,641 | $127 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 242 | $4,925 | $15 |
| Measurement of brain wave activity (eeg), awake and asleep | 25 | $4,502 | $150 |
| Nerve test | 18 | $2,246 | $125 |
| Muscle electrical test | 27 | $1,801 | $62 |
| New patient visit (30+ min) | 13 | $1,380 | $106 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 20 | $560 | $28 |
Who their Medicare patients are
677 Original Medicare patients in 2024. Average age 78 · Under 65 6% · 85 and older 23% · Women 62% · Also on Medicaid 18% · Health risk score 1.47. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Chronic kidney disease 34% · Dementia 34% · Diabetes 31% · Depression 30% · Coronary heart disease 28% · Stroke 22% · Atrial fibrillation 20% · Cancer 18% · Heart failure 16% · COPD 15%.
The office billed $1,217,912, Medicare allowed $312,923 and paid $232,783; for 10,645 services of 19 kinds; $42,713 of it was for drugs given in the office and $190,070 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 677 | 10,645 | 78 | 1.47 | $1,217,912 | $232,783 |
| 2023 | 733 | 7,072 | 77 | 1.56 | $917,320 | $213,852 |
| 2022 | 795 | 7,274 | 77 | 1.51 | $963,951 | $216,100 |
| 2021 | 735 | 7,598 | 77 | 1.45 | $1,002,447 | $240,024 |
| 2020 | 661 | 6,206 | 77 | 1.66 | $988,096 | $202,842 |
| 2019 | 665 | 5,592 | 76 | 1.51 | $1,034,867 | $220,905 |
| 2018 | 611 | 6,788 | 77 | 1.70 | $936,584 | $221,760 |
| 2017 | 592 | 6,331 | 76 | 1.58 | $809,822 | $200,949 |
| 2016 | 665 | 8,142 | 76 | 1.74 | $920,227 | $229,985 |
| 2015 | 607 | 6,588 | 76 | 1.74 | $732,697 | $214,329 |
| 2014 | 529 | 4,801 | 76 | 1.62 | $501,731 | $176,445 |
| 2013 | 473 | 4,452 | 75 | 1.63 | $415,358 | $175,696 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Return visit (30+ min) | 372 | $63,656 | $108 |
| Long return visit (40+ min) | 224 | $45,143 | $155 |
| Botox | 13 | $25,624 | None |
| Short return visit (20+ min) | 211 | $21,541 | $75 |
| New patient visit (45+ min) | 128 | $17,375 | $136 |
| New patient visit (60+ min) | 66 | $12,447 | $189 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $5,542 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $5,168 | $105 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 16 | $4,717 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,527 | $70 |
| Measurement of brain wave activity (eeg), awake and asleep | 36 | $1,987 | $50 |
| Muscle electrical test | 13 | $1,526 | $69 |
| New patient visit (30+ min) | 18 | $1,365 | $76 |
| Telehealth originating site facility fee | 51 | $1,196 | $22 |
| Measurement of brain wave activity (eeg), awake and asleep | 15 | $814 | $51 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 16 | $415 | $26 |
2022: 14 services
| Return visit (30+ min) | 390 | $61,850 | $104 |
| Long return visit (40+ min) | 204 | $43,917 | $153 |
| Botox | 11 | $26,086 | None |
| New patient visit (45+ min) | 195 | $25,195 | $129 |
| Short return visit (20+ min) | 190 | $17,009 | $72 |
| New patient visit (60+ min) | 77 | $14,918 | $194 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,344 | $171 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 11 | $3,802 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $3,522 | $88 |
| Measurement of brain wave activity (eeg), awake and asleep | 58 | $3,074 | $49 |
| New patient visit (30+ min) | 28 | $2,608 | $93 |
| Muscle electrical test | 12 | $1,629 | $102 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,246 | $62 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 13 | $352 | $27 |
2021: 14 services
| Return visit (30+ min) | 363 | $70,505 | $111 |
| Long return visit (40+ min) | 187 | $43,850 | $164 |
| New patient visit (45+ min) | 210 | $29,644 | $141 |
| Botox | 11 | $27,248 | None |
| New patient visit (60+ min) | 79 | $15,749 | $199 |
| Short return visit (20+ min) | 130 | $12,508 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 44 | $8,717 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $7,085 | $182 |
| Telephone medical discussion with physician, 21-30 minutes | 35 | $3,125 | $87 |
| Measurement of brain wave activity (eeg), awake and asleep | 51 | $3,070 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,868 | $64 |
| New patient visit (30+ min) | 29 | $2,588 | $89 |
| Muscle electrical test | 12 | $1,836 | $97 |
| Administration of influenza virus vaccine | 11 | $234 | $21 |
2020: 19 services
| Return visit (30+ min) | 339 | $52,780 | $91 |
| New patient visit (45+ min) | 180 | $25,626 | $142 |
| Long return visit (40+ min) | 142 | $23,915 | $127 |
| New patient visit (60+ min) | 63 | $11,907 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $10,720 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 55 | $9,691 | $170 |
| Short return visit (20+ min) | 107 | $7,702 | $60 |
| Telephone medical discussion with physician, 21-30 minutes | 46 | $5,931 | $104 |
| Muscle electrical test | 31 | $4,280 | $93 |
| Measurement of brain wave activity (eeg), awake and asleep | 67 | $4,143 | $54 |
| Nerve test | 16 | $3,070 | $192 |
| Extended office or other outpatient service, first hour | 20 | $2,907 | $121 |
| Telephone medical discussion with physician, 11-20 minutes | 34 | $2,675 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,207 | $67 |
| Nerve test | 12 | $1,592 | $122 |
| New patient visit (30+ min) | 15 | $1,448 | $97 |
| Influenza vaccine split virus, preservative free | 19 | $1,159 | $61 |
| Extended inpatient or observation hospital service, first hour | 11 | $1,022 | $85 |
| Administration of influenza virus vaccine | 19 | $391 | $21 |
2019: 17 services
| Return visit (30+ min) | 368 | $66,652 | $93 |
| Long return visit (40+ min) | 182 | $35,676 | $130 |
| New patient visit (45+ min) | 206 | $29,481 | $143 |
| New patient visit (60+ min) | 66 | $12,046 | $183 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $8,674 | $91 |
| Muscle electrical test | 56 | $8,443 | $91 |
| Short return visit (20+ min) | 106 | $7,060 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,322 | $176 |
| Nerve test | 19 | $4,051 | $193 |
| Measurement of brain wave activity (eeg), awake and asleep | 58 | $3,538 | $53 |
| Nerve test | 23 | $3,378 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $3,213 | $66 |
| New patient visit (30+ min) | 25 | $2,415 | $97 |
| Extended office or other outpatient service, first hour | 17 | $2,262 | $119 |
| Nerve test | 12 | $1,464 | $122 |
| Follow-up observation care per day, typically 35 minutes | 12 | $1,421 | $95 |
| Extended inpatient or observation hospital service, first hour | 11 | $924 | $84 |
2018: 16 services
| Return visit (30+ min) | 354 | $71,193 | $93 |
| New patient visit (45+ min) | 171 | $24,087 | $141 |
| Long return visit (40+ min) | 102 | $18,444 | $130 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 77 | $15,051 | $175 |
| New patient visit (60+ min) | 64 | $11,781 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 62 | $7,632 | $65 |
| Short return visit (20+ min) | 96 | $6,830 | $57 |
| Muscle electrical test | 51 | $6,622 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $6,485 | $93 |
| Measurement of brain wave activity (eeg), awake and asleep | 23 | $6,442 | $239 |
| Nerve test | 23 | $4,604 | $192 |
| Extended office or other outpatient service, first hour | 24 | $2,937 | $117 |
| Nerve test | 18 | $2,356 | $124 |
| Measurement of brain wave activity (eeg), awake and asleep | 32 | $2,049 | $53 |
| New patient visit (30+ min) | 19 | $1,904 | $100 |
| Nerve test | 12 | $1,774 | $148 |
2017: 17 services
| Return visit (30+ min) | 364 | $73,786 | $92 |
| New patient visit (45+ min) | 185 | $25,798 | $139 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $16,644 | $177 |
| Short return visit (20+ min) | 164 | $13,244 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 82 | $12,144 | $63 |
| Long return visit (40+ min) | 41 | $6,467 | $127 |
| Muscle electrical test | 58 | $6,288 | $74 |
| Nerve test | 21 | $3,766 | $179 |
| New patient visit (60+ min) | 18 | $3,166 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $2,739 | $91 |
| Nerve test | 23 | $2,647 | $115 |
| Initial hospital observation care per day, typically 70 minutes | 14 | $2,441 | $163 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 38 | $2,388 | $34 |
| Measurement of brain wave activity (eeg), awake and asleep | 24 | $1,397 | $52 |
| Nerve test | 15 | $1,262 | $84 |
| Follow-up observation care per day, typically 25 minutes | 13 | $960 | $64 |
| Measurement of brain wave activity (eeg), awake and asleep | 15 | $828 | $52 |
2016: 18 services
| Return visit (30+ min) | 366 | $68,246 | $91 |
| New patient visit (45+ min) | 219 | $30,234 | $138 |
| Botox | 11 | $26,578 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 123 | $24,738 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 123 | $23,419 | $172 |
| Short return visit (20+ min) | 168 | $12,849 | $61 |
| Initial hospital observation care per day, typically 70 minutes | 40 | $6,533 | $159 |
| Long return visit (40+ min) | 33 | $4,955 | $124 |
| Muscle electrical test | 59 | $4,672 | $52 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,555 | $89 |
| Nerve test | 29 | $3,245 | $112 |
| New patient visit (60+ min) | 17 | $3,050 | $179 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 49 | $3,029 | $34 |
| Nerve test | 18 | $1,653 | $92 |
| Measurement of brain wave activity (eeg), awake and asleep | 26 | $1,540 | $50 |
| Follow-up observation care per day, typically 25 minutes | 21 | $1,505 | $63 |
| Nerve test | 17 | $1,307 | $77 |
| Measurement of brain wave activity (eeg), awake and asleep | 11 | $658 | $51 |
2015: 17 services
| Return visit (30+ min) | 275 | $55,205 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 154 | $30,189 | $175 |
| New patient visit (45+ min) | 178 | $24,567 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 136 | $23,093 | $62 |
| Short return visit (20+ min) | 180 | $15,789 | $62 |
| Initial hospital observation care per day, typically 70 minutes | 44 | $7,181 | $160 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 79 | $4,934 | $34 |
| Nerve test | 31 | $4,787 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,308 | $90 |
| Muscle electrical test | 58 | $4,082 | $44 |
| Nerve test | 19 | $2,213 | $116 |
| Follow-up observation care per day, typically 25 minutes | 24 | $2,197 | $63 |
| New patient visit (30+ min) | 26 | $2,192 | $84 |
| Long return visit (40+ min) | 13 | $1,682 | $129 |
| Measurement of brain wave activity (eeg), awake and asleep | 23 | $1,264 | $51 |
| Short return visit | 14 | $559 | $40 |
| Follow-up observation care per day, typically 15 minutes | 12 | $474 | $34 |
2014: 16 services
| Return visit (30+ min) | 245 | $44,359 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 155 | $29,026 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 153 | $24,199 | $62 |
| New patient visit (45+ min) | 116 | $15,779 | $136 |
| Short return visit (20+ min) | 149 | $12,430 | $61 |
| Initial hospital observation care per day, typically 70 minutes | 32 | $5,085 | $159 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,089 | $89 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 62 | $3,959 | $34 |
| Nerve test | 21 | $3,218 | $153 |
| Follow-up observation care per day, typically 25 minutes | 36 | $3,186 | $62 |
| Muscle electrical test | 46 | $3,114 | $40 |
| New patient visit (30+ min) | 31 | $2,773 | $89 |
| Long return visit (40+ min) | 20 | $2,536 | $127 |
| Nerve test | 17 | $2,087 | $123 |
| Measurement of brain wave activity (eeg), awake and asleep | 26 | $1,511 | $50 |
| Return visit (30+ min) | 13 | $946 | $68 |
2013: 13 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 178 | $32,923 | $167 |
| Return visit (30+ min) | 185 | $31,303 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 154 | $24,136 | $60 |
| Measurement of brain wave activity (eeg), awake and asleep | 30 | $17,435 | $447 |
| New patient visit (45+ min) | 121 | $17,296 | $143 |
| Short return visit (20+ min) | 168 | $15,230 | $59 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 76 | $4,024 | $33 |
| Muscle electrical test | 37 | $3,928 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $2,878 | $87 |
| Nerve test | 12 | $2,035 | $170 |
| Long return visit (40+ min) | 12 | $1,655 | $127 |
| Nerve test | 11 | $1,175 | $107 |
| Measurement of brain wave activity (eeg), awake and asleep | 19 | $948 | $45 |
Drugs they prescribed that Part D paid
$381,240
Pharmacies billed $381,240 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,749) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
2,626 generic and fewer than 11 brand-name prescriptions · $381,240 in drug cost · 80 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tecfidera | None | 11 | $97,006 | $8,819 |
| Aimovig | Migraine | 23 | $30,692 | $1,334 |
| Nurtec Odt | None | 16 | $27,345 | $1,709 |
| Namzaric | None | 21 | $24,909 | $1,186 |
| Ajovy | None | 17 | $12,026 | $707 |
See all 40 drugs
| Tecfidera | None | 11 | $97,006 | $8,819 |
| Aimovig | Migraine | 23 | $30,692 | $1,334 |
| Nurtec Odt | None | 16 | $27,345 | $1,709 |
| Namzaric | None | 21 | $24,909 | $1,186 |
| Ajovy | None | 17 | $12,026 | $707 |
| Memantine | None | 217 | $8,503 | $39 |
| Donepezil | None | 539 | $7,970 | $15 |
| Levetiracetam | None | 182 | $5,903 | $32 |
| Rivastigmine | None | 17 | $5,484 | $323 |
| Memantine Hcl Er | None | 34 | $4,503 | $132 |
| Carbidopa-Levodopa | None | 145 | $4,155 | $29 |
| Gabapentin | None | 131 | $2,981 | $23 |
| Rivastigmine | None | 32 | $2,907 | $91 |
| Oxcarbazepine | None | 39 | $2,513 | $64 |
| Pregabalin | None | 42 | $2,419 | $58 |
| Topiramate | None | 111 | $2,368 | $21 |
| Rizatriptan | None | 67 | $2,276 | $34 |
| Nortriptyline | None | 94 | $1,730 | $18 |
| Carbidopa-Levodopa Er | None | 28 | $1,542 | $55 |
| Lamotrigine | None | 41 | $1,480 | $36 |
| Primidone | None | 77 | $1,299 | $17 |
| Mirtazapine | None | 45 | $1,290 | $29 |
| Ropinirole | None | 46 | $1,142 | $25 |
| Baclofen | None | 18 | $1,021 | $57 |
| Quetiapine | None | 62 | $983 | $16 |
| Escitalopram | None | 68 | $939 | $14 |
| Pramipexole Dihydrochloride | None | 50 | $817 | $16 |
| Clopidogrel | None | 34 | $767 | $23 |
| Amantadine | None | 25 | $744 | $30 |
| Sertraline | None | 60 | $724 | $12 |
| Atorvastatin | None | 66 | $685 | $10 |
| Entacapone | None | 12 | $655 | $55 |
| Divalproex | None | 13 | $587 | $45 |
| Eletriptan Hbr | None | 13 | $566 | $44 |
| Venlafaxine Hcl Er | None | 28 | $456 | $16 |
| Sumatriptan | None | 17 | $372 | $22 |
| Valproic Acid | None | 12 | $309 | $26 |
| Lorazepam | None | 89 | $290 | $3 |
| Propranolol | None | 15 | $271 | $18 |
| Tizanidine | None | 15 | $111 | $7 |
Year by year
| 2024 | 2,749 | 570 | 0% (0) | None | $381,240 |
| 2023 | 2,799 | 526 | None | 4% | $510,823 |
| 2022 | 2,929 | 525 | None | None | $602,631 |
| 2021 | 2,859 | 495 | 1% (23) | 4% | $389,005 |
| 2020 | 2,564 | 450 | 1% (13) | 6% | $393,153 |
| 2019 | 2,449 | 402 | None | 8% | $392,594 |
| 2018 | 2,195 | 346 | 1% (22) | None | $342,905 |
| 2017 | 2,384 | 304 | 1% (18) | None | $396,405 |
| 2016 | 2,361 | 323 | 2% (35) | None | $388,319 |
| 2015 | 1,830 | 273 | 2% (35) | None | $299,816 |
| 2014 | 1,380 | 206 | 2% (26) | None | $264,350 |
| 2013 | 1,273 | 180 | 2% (26) | 30% | $239,969 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 37 drugs
| Copaxone | None | 12 | $86,238 | $7,187 |
| Aimovig | Migraine | 24 | $39,560 | $1,648 |
| Namzaric | None | 18 | $25,637 | $1,424 |
| Donepezil | None | 527 | $14,518 | $28 |
| Memantine | None | 235 | $14,431 | $61 |
| Lacosamide | None | 12 | $13,001 | $1,083 |
| Levetiracetam | None | 191 | $9,864 | $52 |
| Carbidopa-Levodopa | None | 182 | $7,294 | $40 |
| Rivastigmine | None | 18 | $5,908 | $328 |
| Memantine Hcl Er | None | 22 | $5,443 | $247 |
| Rivastigmine | None | 35 | $4,475 | $128 |
| Nortriptyline | None | 119 | $3,983 | $33 |
| Topiramate | None | 110 | $3,826 | $35 |
| Gabapentin | None | 139 | $3,234 | $23 |
| Primidone | None | 88 | $2,697 | $31 |
| Oxcarbazepine | None | 33 | $2,666 | $81 |
| Rizatriptan | None | 54 | $2,499 | $46 |
| Quetiapine | None | 53 | $2,195 | $41 |
| Ropinirole | None | 56 | $1,905 | $34 |
| Escitalopram | None | 96 | $1,904 | $20 |
| Divalproex | None | 46 | $1,811 | $39 |
| Atorvastatin | None | 66 | $1,759 | $27 |
| Baclofen | None | 13 | $1,561 | $120 |
| Lamotrigine | None | 34 | $1,428 | $42 |
| Pregabalin | None | 22 | $1,212 | $55 |
| Midodrine | None | 12 | $1,168 | $97 |
| Pramipexole Dihydrochloride | None | 36 | $1,114 | $31 |
| Phenobarbital | None | 12 | $1,055 | $88 |
| Mirtazapine | None | 42 | $973 | $23 |
| Clopidogrel | None | 41 | $965 | $24 |
| Olanzapine | None | 13 | $739 | $57 |
| Sumatriptan | None | 22 | $651 | $30 |
| Sertraline | None | 59 | $584 | $10 |
| Lorazepam | None | 76 | $381 | $5 |
| Venlafaxine Hcl Er | None | 11 | $302 | $27 |
| Propranolol | None | 13 | $261 | $20 |
| Trazodone | None | 14 | $30 | $2 |
2022: 43 drugs
| Copaxone | None | 18 | $145,551 | $8,086 |
| Tecfidera | None | 12 | $113,709 | $9,476 |
| Neupro | None | 17 | $35,888 | $2,111 |
| Aimovig | Migraine | 26 | $34,498 | $1,327 |
| Namzaric | None | 32 | $30,542 | $954 |
| Rivastigmine | None | 31 | $12,938 | $417 |
| Memantine | None | 215 | $12,255 | $57 |
| Carbidopa | None | 13 | $11,107 | $854 |
| Vimpat | None | 11 | $10,612 | $965 |
| Carbidopa-Levodopa | None | 249 | $8,369 | $34 |
| Donepezil | None | 498 | $8,323 | $17 |
| Levetiracetam | None | 162 | $6,885 | $43 |
| Quetiapine | None | 52 | $6,027 | $116 |
| Memantine Hcl Er | None | 18 | $4,756 | $264 |
| Topiramate | None | 129 | $4,011 | $31 |
| Gabapentin | None | 123 | $3,377 | $27 |
| Nortriptyline | None | 133 | $3,321 | $25 |
| Divalproex | None | 75 | $2,965 | $40 |
| Escitalopram | None | 151 | $2,446 | $16 |
| Ropinirole | None | 78 | $2,242 | $29 |
| Rizatriptan | None | 51 | $2,216 | $43 |
| Duloxetine | None | 18 | $2,168 | $120 |
| Carbidopa-Levodopa Er | None | 13 | $2,168 | $167 |
| Baclofen | None | 13 | $1,891 | $145 |
| Oxcarbazepine | None | 35 | $1,773 | $51 |
| Rivastigmine | None | 15 | $1,672 | $111 |
| Divalproex Sodium Er | None | 12 | $1,592 | $133 |
| Amantadine | None | 14 | $1,374 | $98 |
| Pyridostigmine | None | 11 | $1,362 | $124 |
| Primidone | None | 79 | $1,361 | $17 |
| Pramipexole Dihydrochloride | None | 41 | $1,171 | $29 |
| Atorvastatin | None | 55 | $958 | $17 |
| Lamotrigine | None | 34 | $946 | $28 |
| Mirtazapine | None | 46 | $848 | $18 |
| Clopidogrel | None | 41 | $833 | $20 |
| Sertraline | None | 68 | $730 | $11 |
| Propranolol | None | 13 | $696 | $54 |
| Pregabalin | None | 16 | $425 | $27 |
| Lorazepam | None | 95 | $325 | $3 |
| Venlafaxine Hcl Er | None | 13 | $250 | $19 |
| Fluoxetine | None | 16 | $239 | $15 |
| Diazepam | None | 11 | $201 | $18 |
| Sumatriptan | None | 14 | $190 | $14 |
2021: 43 drugs
| Tecfidera | None | 13 | $114,264 | $8,790 |
| Namzaric | None | 29 | $30,267 | $1,044 |
| Neupro | None | 14 | $30,197 | $2,157 |
| Aimovig | Migraine | 16 | $15,600 | $975 |
| Carbidopa | None | 12 | $12,932 | $1,078 |
| Memantine | None | 164 | $11,892 | $73 |
| Rivastigmine | None | 27 | $11,242 | $416 |
| Carbidopa-Levodopa | None | 215 | $9,660 | $45 |
| Memantine Hcl Er | None | 33 | $8,871 | $269 |
| Donepezil | None | 455 | $7,956 | $17 |
| Levetiracetam | None | 169 | $6,684 | $40 |
| Topiramate | None | 148 | $3,957 | $27 |
| Rivastigmine | None | 37 | $3,047 | $82 |
| Oxcarbazepine | None | 30 | $2,679 | $89 |
| Gabapentin | None | 117 | $2,317 | $20 |
| Ropinirole | None | 67 | $2,278 | $34 |
| Pramipexole Dihydrochloride | None | 66 | $2,232 | $34 |
| Pregabalin | None | 29 | $1,919 | $66 |
| Divalproex Sodium Er | None | 17 | $1,889 | $111 |
| Carbidopa-Levodopa Er | None | 18 | $1,875 | $104 |
| Amantadine | None | 15 | $1,615 | $108 |
| Phenobarbital | None | 17 | $1,578 | $93 |
| Duloxetine | None | 15 | $1,476 | $98 |
| Baclofen | None | 11 | $1,296 | $118 |
| Atorvastatin | None | 69 | $1,291 | $19 |
| Mirtazapine | None | 56 | $1,282 | $23 |
| Nortriptyline | None | 111 | $1,266 | $11 |
| Escitalopram | None | 93 | $1,216 | $13 |
| Lamotrigine | None | 49 | $1,144 | $23 |
| Pyridostigmine | None | 43 | $1,085 | $25 |
| Sertraline | None | 88 | $947 | $11 |
| Rizatriptan | None | 14 | $844 | $60 |
| Propranolol | None | 15 | $821 | $55 |
| Primidone | None | 68 | $794 | $12 |
| Clopidogrel | None | 46 | $652 | $14 |
| Divalproex | None | 25 | $559 | $22 |
| Quetiapine | None | 44 | $527 | $12 |
| Lorazepam | None | 105 | $497 | $5 |
| Fluoxetine | None | 14 | $412 | $29 |
| Venlafaxine Hcl Er | None | 16 | $259 | $16 |
| Sumatriptan | None | 28 | $233 | $8 |
| Diazepam | None | 13 | $162 | $12 |
| Tramadol | None | 13 | $17 | $1 |
2020: 47 drugs
| Namzaric | 38 | $34,047 | $896 |
| Neupro | 27 | $32,638 | $1,209 |
| Trokendi Xr | 15 | $16,629 | $1,109 |
| Carbidopa | 12 | $13,429 | $1,119 |
| Memantine Hcl Er | 51 | $12,407 | $243 |
| Carbidopa-Levodopa | 218 | $9,609 | $44 |
| Memantine | 134 | $9,063 | $68 |
| Rasagiline Mesylate | 11 | $8,624 | $784 |
| Ajovy | 12 | $8,430 | $702 |
| Donepezil | 411 | $7,371 | $18 |
| Rivastigmine | 12 | $6,070 | $506 |
| Levetiracetam | 158 | $6,016 | $38 |
| Oxcarbazepine | 35 | $3,829 | $109 |
| Topiramate | 149 | $3,810 | $26 |
| Rivastigmine | 36 | $2,895 | $80 |
| Gabapentin | 107 | $2,487 | $23 |
| Amantadine | 23 | $2,245 | $98 |
| Baclofen | 14 | $2,240 | $160 |
| Carbidopa-Levodopa Er | 11 | $2,216 | $201 |
| Ropinirole | 58 | $1,912 | $33 |
| Eletriptan Hbr | 13 | $1,613 | $124 |
| Mirtazapine | 55 | $1,601 | $29 |
| Divalproex Sodium Er | 13 | $1,570 | $121 |
| Pyridostigmine | 20 | $1,458 | $73 |
| Phenobarbital | 17 | $1,445 | $85 |
| Pregabalin | 20 | $1,364 | $68 |
| Fluoxetine | 21 | $1,159 | $55 |
| Sertraline | 83 | $1,104 | $13 |
| Lamotrigine | 39 | $1,095 | $28 |
| Duloxetine | 16 | $1,026 | $64 |
| Quetiapine | 49 | $880 | $18 |
| Nortriptyline | 48 | $850 | $18 |
| Pramipexole Dihydrochloride | 54 | $849 | $16 |
| Atorvastatin | 40 | $700 | $18 |
| Clopidogrel | 37 | $647 | $17 |
| Primidone | 38 | $641 | $17 |
| Venlafaxine Hcl Er | 30 | $638 | $21 |
| Rizatriptan | 14 | $539 | $39 |
| Propranolol | 11 | $465 | $42 |
| Sumatriptan | 18 | $461 | $26 |
| Escitalopram | 57 | $443 | $8 |
| Divalproex | 27 | $301 | $11 |
| Clonazepam | 21 | $227 | $11 |
| Diazepam | 11 | $204 | $19 |
| Lorazepam | 82 | $188 | $2 |
| Citalopram Hbr | 27 | $176 | $7 |
| Butalbital-Acetaminophen-Caffe | 17 | $85 | $5 |
2019: 39 drugs
| Neupro | None | 31 | $38,320 | $1,236 |
| Namzaric | None | 46 | $37,917 | $824 |
| Lyrica | None | 35 | $20,901 | $597 |
| Memantine Hcl Er | None | 61 | $18,301 | $300 |
| Memantine | None | 147 | $12,358 | $84 |
| Rivastigmine | None | 24 | $8,931 | $372 |
| Aimovig | Migraine | 11 | $6,763 | $615 |
| Carbidopa-Levodopa | None | 228 | $6,613 | $29 |
| Donepezil | None | 343 | $5,950 | $17 |
| Levetiracetam | None | 128 | $4,596 | $36 |
| Rivastigmine | None | 45 | $3,545 | $79 |
| Gabapentin | None | 99 | $3,374 | $34 |
| Oxcarbazepine | None | 39 | $3,248 | $83 |
| Topiramate | None | 117 | $2,182 | $19 |
| Escitalopram | None | 89 | $1,728 | $19 |
| Entacapone | None | 12 | $1,586 | $132 |
| Amantadine | None | 26 | $1,524 | $59 |
| Duloxetine | None | 23 | $1,521 | $66 |
| Ropinirole | None | 37 | $1,372 | $37 |
| Mirtazapine | None | 62 | $1,372 | $22 |
| Phenobarbital | None | 13 | $1,206 | $93 |
| Pregabalin | None | 11 | $1,059 | $96 |
| Rizatriptan | None | 19 | $723 | $38 |
| Sertraline | None | 91 | $710 | $8 |
| Lamotrigine | None | 31 | $671 | $22 |
| Sumatriptan | None | 28 | $666 | $24 |
| Primidone | None | 45 | $623 | $14 |
| Venlafaxine Hcl Er | None | 33 | $568 | $17 |
| Pramipexole Dihydrochloride | None | 41 | $542 | $13 |
| Nortriptyline | None | 32 | $414 | $13 |
| Quetiapine | None | 28 | $363 | $13 |
| Clopidogrel | None | 22 | $329 | $15 |
| Propranolol | None | 21 | $291 | $14 |
| Olanzapine | None | 17 | $190 | $11 |
| Lorazepam | None | 62 | $189 | $3 |
| Clonazepam | None | 20 | $166 | $8 |
| Fluoxetine | None | 21 | $160 | $8 |
| Atorvastatin | None | 12 | $143 | $12 |
| Citalopram Hbr | None | 18 | $79 | $4 |
2018: 40 drugs
| Neupro | 31 | $36,276 | $1,170 |
| Lyrica | 49 | $34,645 | $707 |
| Namzaric | 34 | $26,149 | $769 |
| Memantine Hcl Er | 56 | $23,987 | $428 |
| Namenda Xr | 38 | $23,300 | $613 |
| Carbidopa | 12 | $11,445 | $954 |
| Rivastigmine | 33 | $10,737 | $325 |
| Memantine | 117 | $8,896 | $76 |
| Carbidopa-Levodopa | 199 | $5,477 | $28 |
| Donepezil | 282 | $4,389 | $16 |
| Levetiracetam | 127 | $4,120 | $32 |
| Propranolol Hcl Er | 15 | $2,396 | $160 |
| Oxcarbazepine | 33 | $2,078 | $63 |
| Pyridostigmine | 19 | $1,953 | $103 |
| Escitalopram | 87 | $1,680 | $19 |
| Topiramate | 72 | $1,629 | $23 |
| Rivastigmine | 14 | $1,485 | $106 |
| Dilantin | 12 | $1,338 | $111 |
| Sertraline | 133 | $1,193 | $9 |
| Gabapentin | 66 | $1,107 | $17 |
| Mirtazapine | 59 | $897 | $15 |
| Primidone | 62 | $888 | $14 |
| Pramipexole Dihydrochloride | 43 | $813 | $19 |
| Ropinirole | 30 | $790 | $26 |
| Venlafaxine Hcl Er | 32 | $586 | $18 |
| Rizatriptan | 17 | $583 | $34 |
| Nortriptyline | 32 | $526 | $16 |
| Clopidogrel | 26 | $417 | $16 |
| Lorazepam | 68 | $400 | $6 |
| Lamotrigine | 22 | $399 | $18 |
| Clonazepam | 25 | $336 | $13 |
| Quetiapine | 19 | $284 | $15 |
| Sumatriptan | 18 | $228 | $13 |
| Atorvastatin | 16 | $223 | $14 |
| Olanzapine | 21 | $181 | $9 |
| Butalbital-Acetaminophen-Caffe | 11 | $171 | $16 |
| Simvastatin | 19 | $101 | $5 |
| Fluoxetine | 11 | $97 | $9 |
| Citalopram Hbr | 20 | $61 | $3 |
| Propranolol | 16 | $39 | $2 |
2017: 43 drugs
| Namenda Xr | 200 | $99,322 | $497 |
| Neupro | 32 | $32,479 | $1,015 |
| Namzaric | 67 | $32,267 | $482 |
| Rasagiline Mesylate | 38 | $23,248 | $612 |
| Lyrica | 44 | $20,338 | $462 |
| Carbidopa | 12 | $11,810 | $984 |
| Vimpat | 12 | $9,783 | $815 |
| Rivastigmine | 21 | $7,414 | $353 |
| Aspirin-Dipyridamole Er | 11 | $6,858 | $623 |
| Donepezil | 387 | $4,241 | $11 |
| Memantine | 62 | $3,857 | $62 |
| Rivastigmine | 27 | $3,832 | $142 |
| Levetiracetam | 154 | $3,463 | $22 |
| Carbidopa-Levodopa | 170 | $3,455 | $20 |
| Entacapone | 12 | $3,394 | $283 |
| Amantadine | 25 | $2,740 | $110 |
| Pyridostigmine | 16 | $2,157 | $135 |
| Oxcarbazepine | 37 | $1,856 | $50 |
| Carbidopa-Levodopa-Entacapone | 15 | $1,836 | $122 |
| Pramipexole Dihydrochloride | 69 | $1,171 | $17 |
| Escitalopram | 94 | $1,096 | $12 |
| Dilantin | 11 | $1,094 | $99 |
| Primidone | 80 | $1,045 | $13 |
| Rizatriptan | 26 | $963 | $37 |
| Ropinirole | 39 | $949 | $24 |
| Topiramate | 32 | $772 | $24 |
| Sertraline | 57 | $594 | $10 |
| Venlafaxine Hcl Er | 36 | $566 | $16 |
| Clopidogrel | 42 | $563 | $13 |
| Gabapentin | 46 | $543 | $12 |
| Fluoxetine | 19 | $437 | $23 |
| Baclofen | 20 | $381 | $19 |
| Mirtazapine | 29 | $342 | $12 |
| Nortriptyline | 25 | $315 | $13 |
| Butalbital-Acetaminophen-Caffe | 15 | $272 | $18 |
| Lorazepam | 92 | $257 | $3 |
| Lamotrigine | 18 | $225 | $13 |
| Quetiapine | 23 | $197 | $9 |
| Atorvastatin | 19 | $192 | $10 |
| Simvastatin | 16 | $112 | $7 |
| Clonazepam | 30 | $91 | $3 |
| Olanzapine | 12 | $77 | $6 |
| Citalopram Hbr | 17 | $47 | $3 |
2016: 39 drugs
| Namenda Xr | 207 | $91,851 | $444 |
| Azilect | 48 | $39,932 | $832 |
| Neupro | 38 | $30,542 | $804 |
| Lyrica | 40 | $18,681 | $467 |
| Exelon | 20 | $13,891 | $695 |
| Rivastigmine | 40 | $12,898 | $322 |
| Aspirin-Dipyridamole Er | 16 | $11,320 | $707 |
| Carbidopa | 13 | $7,748 | $596 |
| Donepezil | 466 | $5,126 | $11 |
| Rivastigmine | 49 | $4,578 | $93 |
| Levetiracetam | 158 | $4,256 | $27 |
| Carbidopa-Levodopa-Entacapone | 25 | $3,440 | $138 |
| Pristiq | 11 | $3,173 | $288 |
| Oxcarbazepine | 51 | $3,120 | $61 |
| Memantine | 45 | $3,098 | $69 |
| Carbidopa-Levodopa | 131 | $2,568 | $20 |
| Pramipexole Dihydrochloride | 66 | $2,202 | $33 |
| Amantadine | 15 | $2,044 | $136 |
| Rizatriptan | 25 | $1,742 | $70 |
| Gabapentin | 97 | $1,244 | $13 |
| Primidone | 55 | $1,227 | $22 |
| Fluoxetine | 24 | $1,145 | $48 |
| Escitalopram | 62 | $1,037 | $17 |
| Ropinirole | 32 | $869 | $27 |
| Clopidogrel | 32 | $558 | $17 |
| Lamotrigine | 16 | $462 | $29 |
| Nortriptyline | 35 | $449 | $13 |
| Topiramate | 22 | $429 | $19 |
| Lorazepam | 94 | $394 | $4 |
| Hydrocodone-Ibuprofen | 12 | $375 | $31 |
| Mirtazapine | 20 | $351 | $18 |
| Quetiapine | 44 | $334 | $8 |
| Venlafaxine Hcl Er | 13 | $332 | $26 |
| Simvastatin | 17 | $254 | $15 |
| Atorvastatin | 21 | $218 | $10 |
| Clonazepam | 40 | $210 | $5 |
| Paroxetine | 23 | $172 | $7 |
| Sertraline | 32 | $147 | $5 |
| Citalopram Hbr | 15 | $42 | $3 |
2015: 40 drugs
| Rebif | 12 | $66,591 | $5,549 |
| Namenda Xr | 127 | $52,773 | $416 |
| Azilect | 31 | $29,090 | $938 |
| Neupro | 38 | $25,917 | $682 |
| Exelon | 36 | $21,702 | $603 |
| Lyrica | 22 | $12,394 | $563 |
| Zomig | 11 | $8,079 | $734 |
| Namenda | 14 | $4,988 | $356 |
| Ropinirole Er | 16 | $4,078 | $255 |
| Donepezil | 295 | $3,618 | $12 |
| Carbidopa-Levodopa | 143 | $3,385 | $24 |
| Pristiq Er | 13 | $3,205 | $247 |
| Levetiracetam | 88 | $2,413 | $27 |
| Amantadine | 18 | $1,940 | $108 |
| Pramipexole Dihydrochloride | 36 | $1,892 | $53 |
| Galantamine Hbr | 12 | $1,716 | $143 |
| Gabapentin | 95 | $1,536 | $16 |
| Oxcarbazepine | 39 | $1,535 | $39 |
| Rivastigmine | 15 | $1,103 | $74 |
| Carbidopa-Levodopa Er | 13 | $1,017 | $78 |
| Memantine | 12 | $996 | $83 |
| Mirtazapine | 55 | $620 | $11 |
| Nortriptyline | 48 | $611 | $13 |
| Primidone | 29 | $556 | $19 |
| Escitalopram | 26 | $526 | $20 |
| Venlafaxine Hcl Er | 28 | $495 | $18 |
| Topiramate | 47 | $447 | $10 |
| Ropinirole | 26 | $369 | $14 |
| Hydrocodone-Ibuprofen | 12 | $357 | $30 |
| Clopidogrel | 25 | $314 | $13 |
| Sertraline | 49 | $253 | $5 |
| Atorvastatin | 19 | $241 | $13 |
| Quetiapine | 22 | $234 | $11 |
| Paroxetine | 29 | $232 | $8 |
| Lorazepam | 50 | $203 | $4 |
| Simvastatin | 22 | $198 | $9 |
| Clonazepam | 33 | $183 | $6 |
| Hydrocodone-Acetaminophen | 12 | $138 | $11 |
| Sumatriptan | 11 | $135 | $12 |
| Citalopram Hbr | 15 | $92 | $6 |
2014: 36 drugs
| Rebif | 13 | $65,265 | $5,020 |
| Azilect | 29 | $30,381 | $1,048 |
| Namenda | 70 | $28,253 | $404 |
| Exelon | 56 | $25,873 | $462 |
| Neupro | 40 | $24,407 | $610 |
| Namenda Xr | 65 | $21,606 | $332 |
| Lyrica | 40 | $14,933 | $373 |
| Zomig | 12 | $7,249 | $604 |
| Donepezil | 162 | $5,171 | $32 |
| Ropinirole | 35 | $4,115 | $118 |
| Pristiq Er | 11 | $2,327 | $212 |
| Gabapentin | 89 | $1,893 | $21 |
| Levetiracetam | 71 | $1,889 | $27 |
| Pramipexole Dihydrochloride | 25 | $1,791 | $72 |
| Oxcarbazepine | 38 | $1,718 | $45 |
| Carbidopa-Levodopa | 69 | $1,706 | $25 |
| Amantadine | 15 | $1,344 | $90 |
| Carbidopa-Levodopa Er | 18 | $1,253 | $70 |
| Dantrolene | 12 | $620 | $52 |
| Topiramate | 30 | $565 | $19 |
| Escitalopram | 17 | $467 | $27 |
| Clopidogrel | 22 | $439 | $20 |
| Venlafaxine Hcl Er | 11 | $341 | $31 |
| Primidone | 24 | $337 | $14 |
| Nortriptyline | 30 | $307 | $10 |
| Mirtazapine | 22 | $302 | $14 |
| Simvastatin | 26 | $293 | $11 |
| Atorvastatin | 27 | $277 | $10 |
| Clonazepam | 40 | $205 | $5 |
| Sumatriptan | 11 | $195 | $18 |
| Lorazepam | 27 | $177 | $7 |
| Sertraline | 17 | $139 | $8 |
| Paroxetine | 16 | $116 | $7 |
| Lamotrigine | 13 | $110 | $8 |
| Hydrocodone-Acetaminophen | 11 | $104 | $9 |
| Fluoxetine | 12 | $54 | $4 |
2013: 34 drugs
| Rebif | 13 | $56,774 | $4,367 |
| Namenda | 113 | $39,587 | $350 |
| Exelon | 77 | $30,446 | $395 |
| Azilect | 34 | $28,755 | $846 |
| Lyrica | 38 | $10,409 | $274 |
| Neupro | 26 | $9,394 | $361 |
| Aricept | 23 | $9,350 | $407 |
| Ropinirole | 21 | $3,493 | $166 |
| Rivastigmine | 13 | $3,189 | $245 |
| Donepezil | 114 | $2,847 | $25 |
| Pramipexole Dihydrochloride | 38 | $1,843 | $49 |
| Levetiracetam | 63 | $1,822 | $29 |
| Carbidopa-Levodopa | 58 | $1,656 | $29 |
| Topiramate | 43 | $1,561 | $36 |
| Gabapentin | 46 | $1,287 | $28 |
| Oxcarbazepine | 24 | $1,024 | $43 |
| Amantadine | 12 | $1,023 | $85 |
| Venlafaxine Hcl Er | 13 | $634 | $49 |
| Dantrolene | 11 | $572 | $52 |
| Divalproex | 13 | $356 | $27 |
| Mirtazapine | 30 | $343 | $11 |
| Lamotrigine | 15 | $289 | $19 |
| Clonazepam | 59 | $281 | $5 |
| Simvastatin | 22 | $269 | $12 |
| Primidone | 12 | $259 | $22 |
| Verapamil Er | 11 | $240 | $22 |
| Sertraline | 27 | $223 | $8 |
| Nortriptyline | 18 | $199 | $11 |
| Trihexyphenidyl | 11 | $177 | $16 |
| Paroxetine | 19 | $155 | $8 |
| Lorazepam | 26 | $135 | $5 |
| Verapamil | 12 | $126 | $11 |
| Omeprazole | 11 | $118 | $11 |
| Fluoxetine | 11 | $47 | $4 |
Money from drug and device companies
$262 in 2025
| 2025 | 3 | 3 | None | $262 |
| 2024 | 1 | 1 | None | $124 |
| 2021 | 2 | 2 | None | $252 |
| 2020 | 2 | 3 | None | $161 |
| 2019 | 2 | 9 | None | $386 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| CVRx | Barostim Neo System | $125 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | None | $122 | 1 payment
|
| Ucb | Rystiggo | $15 | 1 payment
|
See all 3 published payments
| CVRx | Meals · 2025-10-14 | Barostim Neo System | $125 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-27 | None | $122 |
| Ucb | Education · 2025-03-11 | Rystiggo | $15 |
See earlier years (2024, 2021, 2020, 2019)
2024: $124
| Boehringer Ingelheim Pharmaceuticals | None | $124 | 1 payment
|
2021: $252
| Silk Road Medical | Enroute Transcarotid Neuroprotection System | $129 | 1 payment
|
| GlaxoSmithKline | Trelegy Ellipta | $123 | 1 payment
|
2020: $161
| Teva Pharmaceuticals USA | Ajovy | $143 | 2 payments
|
| Supernus Pharmaceuticals | Trokendi Xr | $18 | 1 payment
|
2019: $386
| Teva Pharmaceuticals USA | Ajovy | $261 | 8 payments
|
| Amgen | Aimovig | $125 | 1 payment
|
Professional record
- NPI
- 1770560013
- Licence
- CA A79330California A79330: Current · expires 2028-05-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 5575 W Las Positas Blvd Ste 330, Pleasanton, CA, 94588
- NPI first listed
- 2005-12-28
- NPI last updated
- 2023-10-05
- NPI record certified
- 2023-10-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 5575 W. Las Positas Blvd, Pleasanton, CA, 94588